Project 3: Inhibiting FAK to enhance immune checkpoint inhibitor therapy in LKB1-mutant lung adenocarcinoma
项目3:抑制FAK增强免疫检查点抑制剂治疗LKB1突变型肺腺癌
基本信息
- 批准号:10631151
- 负责人:
- 金额:$ 56.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAntibody TherapyCD8-Positive T-LymphocytesCancer PatientCell AdhesionCell CommunicationClinicalCollagenCombined Modality TherapyDataFibroblastsFocal Adhesion Kinase 1GenesGenetically Engineered MouseGenomicsGoalsImmune checkpoint inhibitorImmunotherapeutic agentImmunotherapyInvadedKRAS2 geneKRASG12DLeadLuciferasesLung AdenocarcinomaMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMetastatic Neoplasm to Lymph NodesModelingMusMutateMutationNeoplasm MetastasisNon-Small-Cell Lung CarcinomaPD-1 inhibitorsPathway interactionsPatientsPhase II Clinical TrialsPhenotypePilot ProjectsPre-Clinical ModelPrimary NeoplasmPublishingRegimenRegulationRepressionResistanceSTK11 geneSalvage TherapySubgroupSymptomsT cell infiltrationTestingTherapeuticTimeTumor BurdenTumor Suppressor Proteinsanti-PD-1anti-PD1 antibodiescancer cellcell motilitycheckpoint therapyclinical developmentclinically relevantcohortefficacy evaluationimmune checkpointimprovedinhibitorinhibitor therapykinase inhibitorlymph nodesmolecular targeted therapiesmouse modelmutantneoplastic cellnovelnovel therapeuticspatient populationpembrolizumabpharmacologicpreclinical trialpreventrecruitresponserestorationsynergismtargeted agenttumortumor growthtumor progression
项目摘要
Project Summary
Project 3 of the Emory Lung Cancer P01 application focuses on focal adhesion kinase (FAK) in LKB1-mutant
lung adenocarcinoma (LUAD) for the clinical development of combination therapy to enhance the efficacy of
immune checkpoint inhibitors (ICI). The tumor suppressor LKB1 is the 3rd most frequently mutated gene in lung
adenocarcinoma. This tumor subgroup is resistant to ICI therapy and is not amenable to molecularly targeted
therapies. Our goal is to develop novel therapeutic regimens that will benefit patients with LKB1-mutant lung
cancer. We discovered that LKB1 regulates LUAD cell motility and represses FAK to oversee cell adhesion,
invasion, and collagen remodeling. Our clinically relevant Lkb1-mutant genetically engineered mouse model
(GEMM) showed that FAK is activated in collective invasion packs (CIPs) of cancer cells at the invasion front of
the primary tumor, with a similar phenotype as in lung cancer patients. These collective invasion packs are
surrounded by heterotypic cancer-associated fibroblasts (CAFs) and contain a densely remodeled collagen
matrix. Our initial pre-clinical trial with this mouse model indicated that these tumors are exquisitely sensitive to
FAK inhibition monotherapy. Importantly, FAK inhibitor therapy increases CD8+T cell infiltration and enhances
ICI in pancreatic cancer. Our pilot study revealed synergy between FAK inhibitor and anti-PD-1 antibody in
preventing tumor growth and metastasis in a new metastatic syngeneic model. Here, FAK inhibition eliminates
collective invasion packs, surrounding CAFs, and restores STING expression (a focus of Project 2), increasing
CD8+ T cell infiltration to CIPs. These data lead to the central hypothesis that LKB1 inactivation in LUAD
represents an acquired tumor vulnerability that can be synergistically targeted with a FAK inhibitor in combination
with ICI therapy. We propose that FAK inhibition disrupts the heterotypic CAF:tumor-cell interaction within the
collective invasion packs, resulting in increased CD8+ T-cell infiltration. To test this, we will conduct a Phase II
clinical trial with the FAK inhibitor in combination with an anti-PD-1 antibody (pembrolizumab) in patients with
LKB1-mutant advanced lung adenocarcinoma. We will also evaluate the underlying mechanism using our
GEMM and syngeneic model to determine if pharmacologic FAK inhibition enhances the response to ICI,
resulting in CD8+ T-cell recruitment to collective invasion packs. Along with Project 1 (FAK regulated
glutaminolysis and immune checkpoint regulation) and Project 2 (restoration of STING to enhance ICI), the
successful completion of this project will accelerate the implementation of a novel combination therapy approach
specially tailored toward lung cancer patients with LKB1-mutant tumors.
项目摘要
Emory肺癌P01应用的项目3专注于LKB1突变体中的粘着斑激酶(FAK)
肺腺癌(LUAD)为临床制定综合治疗方案以提高疗效
免疫检查点抑制剂(ICI)。抑癌基因LKB1是肺组织中突变频率第三高的基因
腺癌。该肿瘤亚群对ICI治疗有抵抗力,不能进行分子靶向治疗。
治疗。我们的目标是开发新的治疗方案,使LKB1突变肺患者受益
癌症。我们发现LKB1调节LUAD细胞的运动并抑制FAK来监督细胞黏附,
侵袭和胶原蛋白重塑。我们的临床相关的Lkb1突变基因工程小鼠模型
(GEMM)显示FAK在侵袭前沿的癌细胞的集体侵袭包(CIP)中被激活。
原发肿瘤,与肺癌患者的表型相似。这些集体入侵包是
被异型癌症相关成纤维细胞(CAF)包围,并含有密集重塑的胶原蛋白
矩阵。我们最初对这种小鼠模型进行的临床前试验表明,这些肿瘤对
FAK抑制单药治疗。重要的是,FAK抑制剂治疗增加了CD8+T细胞的浸润,并增强了
胰腺癌的ICI。我们的初步研究揭示了FAK抑制剂和抗PD-1抗体之间的协同作用
在一种新的转移同基因模型中防止肿瘤生长和转移。在这里,FAK抑制消除了
集体入侵包,包围CAF,恢复刺痛表达(项目2的重点),增加
CD8+T细胞在CIPS中的浸润。这些数据导致了LUAD中LKB1失活的中心假设
代表获得性肿瘤易损性,可与FAK抑制剂联合协同靶向
接受ICI治疗。我们认为,抑制FAK破坏了异型CAF:肿瘤-细胞相互作用在
集体侵袭包,导致CD8+T细胞浸润增加。为了测试这一点,我们将进行第二阶段
FAK抑制剂联合抗PD-1抗体(Pembrolizumab)治疗慢性粒细胞白血病的临床试验
LKB1突变的晚期肺腺癌。我们还将使用我们的
GEMM和同基因模型来确定药物FAK抑制是否增强了对ICI的反应,
导致CD8+T细胞向集体侵袭包募集。连同项目1(FAK受监管
谷氨酰胺分解和免疫检查点调节)和项目2(修复刺痛以增强ICI),
该项目的成功完成将加速一种新的联合治疗方法的实施
专为患有LKB1突变肿瘤的肺癌患者量身定做。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adam I. Marcus其他文献
TGF-β1-mediated intercellular signaling fuels cooperative cellular invasion
转化生长因子-β1(TGF-β1)介导的细胞间信号传导促进了细胞的协同侵袭。
- DOI:
10.1016/j.celrep.2025.115315 - 发表时间:
2025-02-25 - 期刊:
- 影响因子:6.900
- 作者:
Tala O. Khatib;Brian A. Pedro;Sergei Bombin;Veronika Y. Matsuk;Isaac E. Robinson;Sarah F. Webster;Landon J. Marcus;Emily R. Summerbell;Gregory K. Tharp;Christina M. Knippler;Pritha Bagchi;Jeanne Kowalski-Muegge;H. Rich Johnston;Homa Ghalei;Paula M. Vertino;Janna K. Mouw;Adam I. Marcus - 通讯作者:
Adam I. Marcus
High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma
- DOI:
10.1007/s00432-025-06269-9 - 发表时间:
2025-07-26 - 期刊:
- 影响因子:2.800
- 作者:
Rebecca E. Parker;Leon McSwain;Wei Zhou;Adam I. Marcus;Haian Fu;Suresh S. Ramalingam;Shirley Zhang;Melissa Gilbert-Ross - 通讯作者:
Melissa Gilbert-Ross
A two dimensional simulation of microtubule dynamics
微管动力学的二维模拟
- DOI:
10.1109/itab.2008.4570630 - 发表时间:
2008 - 期刊:
- 影响因子:0
- 作者:
K. Kong;Adam I. Marcus;P. Giannakakou;Christopher Alberti;May D. Wang - 通讯作者:
May D. Wang
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export
RAS•GTP:RanGAP1 复合物的致癌非经典活性促进核蛋白输出
- DOI:
10.1038/s43018-024-00847-5 - 发表时间:
2024-11-11 - 期刊:
- 影响因子:28.500
- 作者:
Brajendra K. Tripathi;Nicole H. Hirsh;Xiaolan Qian;Marian E. Durkin;Dunrui Wang;Alex G. Papageorge;Ross Lake;Yvonne A. Evrard;Adam I. Marcus;Suresh S. Ramalingam;Mary Dasso;Karen H. Vousden;James H. Doroshow;Kylie J. Walters;Douglas R. Lowy - 通讯作者:
Douglas R. Lowy
Adam I. Marcus的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adam I. Marcus', 18)}}的其他基金
Project 3: Inhibiting FAK to enhance immune checkpoint inhibitor therapy in LKB1-mutant lung adenocarcinoma
项目3:抑制FAK增强免疫检查点抑制剂治疗LKB1突变型肺腺癌
- 批准号:
10411668 - 财政年份:2022
- 资助金额:
$ 56.99万 - 项目类别:
Implications of metabolic heterogeneity on collective lung cancer cell invasion
代谢异质性对肺癌细胞集体侵袭的影响
- 批准号:
10383657 - 财政年份:2021
- 资助金额:
$ 56.99万 - 项目类别:
Spatiotemporal interrogation of metabolic cooperation between heterogenous lung cancer subpopulations in collective cell invasion
集体细胞侵袭中异质肺癌亚群之间代谢合作的时空询问
- 批准号:
10818222 - 财政年份:2021
- 资助金额:
$ 56.99万 - 项目类别:
Implications of metabolic heterogeneity on collective lung cancer cell invasion
代谢异质性对肺癌细胞集体侵袭的影响
- 批准号:
10672179 - 财政年份:2021
- 资助金额:
$ 56.99万 - 项目类别:
Deconstructing the collective invasion pack to define Myo10 function
解构集体入侵包定义Myo10功能
- 批准号:
10611926 - 财政年份:2020
- 资助金额:
$ 56.99万 - 项目类别:
Deconstructing the collective invasion pack to define Myo10 function
解构集体入侵包定义Myo10功能
- 批准号:
10159870 - 财政年份:2020
- 资助金额:
$ 56.99万 - 项目类别:
Deconstructing the collective invasion pack to define Myo10 function
解构集体入侵包定义Myo10功能
- 批准号:
10400713 - 财政年份:2020
- 资助金额:
$ 56.99万 - 项目类别:
Atypical Angiogenic Mimicry During Collective Lung Cancer Invasion
肺癌集体侵袭过程中的非典型血管生成拟态
- 批准号:
10439630 - 财政年份:2019
- 资助金额:
$ 56.99万 - 项目类别:
Atypical Angiogenic Mimicry During Collective Lung Cancer Invasion
肺癌集体侵袭过程中的非典型血管生成拟态
- 批准号:
9973155 - 财政年份:2019
- 资助金额:
$ 56.99万 - 项目类别:
相似海外基金
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
- 批准号:
MR/Y008847/1 - 财政年份:2024
- 资助金额:
$ 56.99万 - 项目类别:
Research Grant
Development of CD81 Antibody Therapy for Osteosarcoma - Focused on Exosomes -
骨肉瘤 CD81 抗体疗法的开发 - 专注于外泌体 -
- 批准号:
23K08593 - 财政年份:2023
- 资助金额:
$ 56.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
IN-002 的 GMP 生产和 IND 备案,这是一种针对呼吸道合胞病毒的有效吸入粘液捕获抗体疗法
- 批准号:
10761398 - 财政年份:2023
- 资助金额:
$ 56.99万 - 项目类别:
SBIR Phase I: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells
SBIR 第一期:通过抗体依赖性细胞介导的自然杀伤细胞的细胞毒性机制,针对急性髓性白血病新抗原的抗体疗法
- 批准号:
2246487 - 财政年份:2023
- 资助金额:
$ 56.99万 - 项目类别:
Standard Grant
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
- 批准号:
10511223 - 财政年份:2022
- 资助金额:
$ 56.99万 - 项目类别:
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
- 批准号:
10643886 - 财政年份:2022
- 资助金额:
$ 56.99万 - 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
- 批准号:
10511323 - 财政年份:2022
- 资助金额:
$ 56.99万 - 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
- 批准号:
10657706 - 财政年份:2022
- 资助金额:
$ 56.99万 - 项目类别:
Hacking Co-Stimulatory Receptors with Targeted Checkpoint Antibody Therapy
用靶向检查点抗体疗法攻击共刺激受体
- 批准号:
574961-2022 - 财政年份:2022
- 资助金额:
$ 56.99万 - 项目类别:
University Undergraduate Student Research Awards
Imaging the multifaceted response to a bispecific antibody therapy
双特异性抗体疗法的多方面反应成像
- 批准号:
10451574 - 财政年份:2021
- 资助金额:
$ 56.99万 - 项目类别: